blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1000033

EP1000033 - HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.03.2005
Database last updated on 23.04.2024
Most recent event   Tooltip11.03.2005No opposition filed within time limitpublished on 27.04.2005  [2005/17]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2000/35]
Former [2000/20]For all designated states
AstraZeneca UK Limited
15 Stanhope Gate
London W1Y 6LN / GB
Inventor(s)01 / JAMES, Roger
Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
02 / NOWAK, Thorsten
Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
03 / WARNER, Peter
Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
[2000/20]
Representative(s)Brown, Andrew Stephen
AstraZeneca PLC Global Intellectual Property Mereside, Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
[N/P]
Former [2000/20]Brown, Andrew Stephen
AstraZeneca PLC Global Intellectual Property Mereside, Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
Application number, filing date98935208.323.07.1998
[2000/20]
WO1998GB02210
Priority number, dateGB1997001589429.07.1997         Original published format: GB 9715894
[2000/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9906371
Date:11.02.1999
Language:EN
[1999/06]
Type: A1 Application with search report 
No.:EP1000033
Date:17.05.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 11.02.1999 takes the place of the publication of the European patent application.
[2000/20]
Type: B1 Patent specification 
No.:EP1000033
Date:06.05.2004
Language:EN
[2004/19]
Search report(s)International search report - published on:EP11.02.1999
ClassificationIPC:C07D213/82, A61K31/455
[2000/20]
CPC:
C07D213/82 (EP,US); C07D213/38 (KR); A61P43/00 (EP);
A61P7/02 (EP); C07D213/71 (KR); C07D237/08 (KR);
C07D237/18 (KR); C07D239/26 (KR); C07D239/38 (KR);
C07D253/02 (KR); C07D257/08 (KR); C07D403/04 (KR);
C07D405/04 (KR); C07D409/04 (KR) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/20]
TitleGerman:HETEROCYCLISCHE VERBINDUNGEN ALS FAKTOR XA INHIBITOREN[2000/20]
English:HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA[2000/20]
French:DERIVES HETEROCYCLIQUES INHIBANT LE FACTEUR XA[2000/20]
Entry into regional phase29.02.2000National basic fee paid 
29.02.2000Designation fee(s) paid 
29.02.2000Examination fee paid 
Examination procedure01.02.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
29.02.2000Examination requested  [2000/20]
20.03.2002Despatch of a communication from the examining division (Time limit: M04)
20.06.2002Reply to a communication from the examining division
17.01.2003Despatch of a communication from the examining division (Time limit: M04)
25.03.2003Reply to a communication from the examining division
02.05.2003Communication of intention to grant the patent
07.08.2003Fee for grant paid
07.08.2003Fee for publishing/printing paid
Divisional application(s)EP03018010.3  / EP1367054
Opposition(s)08.02.2005No opposition filed within time limit [2005/17]
Fees paidRenewal fee
12.07.2000Renewal fee patent year 03
05.07.2001Renewal fee patent year 04
04.07.2002Renewal fee patent year 05
04.07.2003Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO9610022  (ZENECA LTD [GB], et al) [Y] 1-9 * page 111; table IV *;
 [PY]WO9728129  (ZENECA LTD [GB], et al) [PY] 1-9* pages 31-34; claim 1 *;
 [PY]WO9821188  (ZENECA LTD [GB], et al) [PY] 1-9 * pages 19-23; claim 1 *;
 [Y]  - KUNITADA S ET AL, "FACTOR XA INHIBITORS", CURRENT PHARMACEUTICAL DESIGN, (199610), vol. 2, no. 5, pages 531 - 542, XP002057653 [Y] 1-9 * page 539 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.